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SUMMARY
In this comprehensive review we discuss the publications 
reporting pyrazoles derived from curcumin, curcuminoids 
and hemi-curcuminoids (149 examples) together with 
some biological and pharmacological properties.
Key words: Pyrazole; curcumin; curcuminoid; structure; 
biological properties.
RESUMEN
En esta revisión se discuten todas las publicaciones que 
tratan de pirazoles derivados de la curcumina, los curcu-
minoides y los hemi-curcuminoides (en total 149 ejemplos) 
así como algunas propiedades biológicas y farmacológicas.
Palabras clave: Pirazol; curcumina; curcuminoide; estruc-
tura; propiedades biológicas.
RESUM
En aquesta revisió es presenten les publicacions sobre pi-
razoles derivats de curcumina, curcuminoides i hemi-cur-
cuminoides (149 exemples) així com algunes propietats 
biològiques i farmacològiques.
Paraulas clau: Pirazole; curcumina; curcuminoide; estruc-
tura; propietats biològiques.
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INTRODUCTION
We will limit our review to pyrazoles directly derived from 
curcumin or from other b-dicarbonyl compounds related 
to curcumin, i.e. possessing a styryl (save 2, 16 and 133) 
substituent bearing one or both OH and OCH3 substi-
tuents. For general reviews concerning pyrazoles, see refe-
rence (1) and for reviews about curcumin see reference (2).
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Curcuminoid pyrazoles have been discussed in some 
books (3), Master Degrees and Ph. D. Thesis (4), and have 
been the subject of several patents (5), but there is no com-
prehensive review about them. Excluding structures repor-
ted in patents, Figures 1 to 14 contain all the curcuminoid 
pyrazoles reported in the literature and Figures 15 to 17 
those described in our publications. The first synthesis of 
the N-unsubstituted pyrazole derived from curcumin 1 was 
reported by Flynn et al., from the Parke-Davis Pharmaceu-
tical Research Division of the Warner-Lambert Company, in 
1991, and was tested as 5-lipoxygenase and cyclooxygena-
se inhibitor together with compound 2 (saturated branches) 
and the hemicurcuminoid pyrazoles 3-9 of Figure 1 (6).
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Figure 1. The first series of pyrazoles 1-9 de-
rived from curcumin and curcuminoids.
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Figure 3. Compounds 16-29.
N N
H
R1
MeO
R1
30, R1 = OH, R2 = (CH2)2CO2Et
31, R1 = OCH3, R2 = (CH2)2CO2Et
32, R1 = OCH3, R2 = CH3
33, R1 = OCH3, R2 = (CH)2CO2Me
34, R1 = OCH3, R2 = (CH)2CO2Et
35, R1 = OCH3, R2 = (CH)2CONH2
OMe
R2
N N
H
H3CO
H3CO
OCH3
OCH3
OEtO
N N
H
H3CO
H3CO
OCH3
OCH3
OH
34
36
Figure 4. Compounds 30-36.
N N
R
HO
H3CO OCH3
OH
37, R = Br
38, R = NHNH2
39, R = NO
40, R = COCH2Cl
N N
R
HO
H3CO OCH3
OH
41, R = CH2OH
42, R = CHO
N NN
Cl
N
Cl
N N
H
HO
H3CO OCH3
OC4H9
43
N N
H3CO OCH344
H3C
CH3
Figure 5. Compounds 37-44.
N N
R
HO OH
H3CO OCH3
45, R = CH2CO2H
46, R = CH2CONH(CH2CH2O)3H
47, R = CH2CONHCH2C CH
N N
HO OH
H3CO OCH3
N
O
H
N
N
N O
H
3
48
Figure 6. Compounds 45-48.
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Figure 7. Compounds 49-61.
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Figure 10. Compounds 93-96.
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We have prepared two tables to facilitate the search of any 
structure. Table 1 contains the references in chronological 
order (first, those from the literature, then, our publications) 
with the pyrazoles reported in them. Table 2 contains the 
149 pyrazoles and the references where they are reported. 
Table 1. Publications ordered chronologically (from 6 to 64).
1 
 
Table 1. Publications ordered chronologically (from 6 to 64).
Compounds Ref. Compounds Ref.
1, 2, 3, 4, 5, 6, 7, 8, 9 (6) 1, 10, 11, 12, 13, 14 (7)
1, 10, 11, 12, 13, 14 (8) 1, 10, 11 (9) 
1, 10, 11, 15 (10) 12 (11) 
1, 10, 11 (12) 16 (13) 
12 (14) 1, 17, 18, 19[CNB001],20,24, 25, 26 (15) 
1, 19 [CNB001], 20, 21, 22, 23 (16) 1, 17, 19 [CNB001], 21, 24, 25, 26, 27,
28, 29
(17) 
19 [CNB001] (18) 1, 15, 30, 31, 32, 33, 34, 35, 36 (19)
1, 27 (20) 1 (21)
1, 17 (22) 1, 10, 11, 19 [CNB001] (23)
12 (24) 19 [CNB001] (25)
1, 37, 38, 39, 40, 41, 42 (26) 19 [CNB001] (27)
1, 43 (28) 19 [CNB001], 44 [CNB023] (29)
28, 45, 46, 47, 48 (30) 12 (31)
19 [CNB001] (32) 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,
59, 60, 61
(33)
12 (34) 1 (35)
1 (36) 1 (37)
62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77
(38) 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88 (39)
1, 12, 27, 32, 33, 34, 43 (40) 19 [CNB001], 89, 90, 91, 92 (41)
19 [CNB001] (42) 1, 12, 28 (43)
1, 11, 93, 94, 95, 96 (44) 19 [CNB001] (45)
19 [CNB001] (46) 87 (47)
19 [CNB001] (48) 97, 98, 99, 100, 101, 102, 103, 104, 105 (49)
19 [CNB001] (50) 12 (51)
49, 50, 55, 78, 79, 80, 81, 84, 87, 88,
106, 107, 108, 109, 110, 111, 112
(52) 1, 19 [CNB001], 20, 22, 23, 24, 113,
114, 115, 116, 117, 118, 119, 120, 121,
122[Pculin02H], 123, 124
(53)
1, 17, 19 [CNB001], 24, 25, 89, 119,
125, 126
(54) 19 [CNB001], 23, 89, 116, 127 (55)
12 (56) 12 (57)
12 (58) 1, 19 [CNB001], 20, 21, 22, 23, 24, 28,
113, 114, 115, 116, 119, 125, 128, 129,
130
(59)
126, 131, 132, 133 (60) 1, 62, 134, 135, 136, 137, 138 (61)
1, 62, 134, 135, 136, 137 (62) 139, 140, 141, 142, 143, 144 (63)
145, 146, 147, 148, 149 (64)
Table 2. List of compounds from 1 to 149 with 
the figures where they are represented.
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Table 2. List of compounds from 1 to 149 with the figures where they are represented.
Compound References Compound References
1 (Figure 1) (6,7,8,9,10,12,15,16,17,
19,20,21,22,23,26,28,35,
36,37,40,43,44,53,54,59, 61,62)
2 (Figure 1) (6)
3 (Figure 1) (6) 4 (Figure 1) (6) 
5 (Figure 1) (6) 6 (Figure 1) (6)
7 (Figure 1) (6) 8 (Figure 1) (6)
9 (Figure 1) (6) 10 (Figure 2) (7,8,9,10,12,23)
11 (Figure 2) (7,8,9,10,12,23,44) 12 (Figure 2) (7,8,11,14,24,31,34,40,
43,51,56,57,58)
13 (Figure 2) (7,8) 14 (Figure 2) (7,8)
15 (Figure 2) (10,19) 16 (Figure 3) (13)
17 (Figure 3) (15,17,22,54) 18 (Figure 3) (15) 
19 [CNB001] 
(Figure 3)
(15,16,17,18,23,25,27,29,32,41,
42,45,46,48,50,53, 54,55,59)
20 (Figure 3) (15,16,53,59)
21 (Figure 3) (16,17,59) 22 (Figure 3) (16,53,59)
23 (Figure 3) (16,53,55,59) 24 (Figure 3) (15,17,53,54,59)
25 (Figure 3) (15,17,54) 26 (Figure 3) (15,17)
27 (Figure 3) (17,20,40) 28 (Figure 3) (17,30,43,59) 
29 (Figure 3) (17) 30 (Figure 4) (19)
31 (Figure 4) (19) 32 (Figure 4) (19,40)
33 (Figure 4) (19,40) 34 (Figure 4) (19,40)
35 (Figure 4) (19) 36 (Figure 4) (19) 
37 (Figure 5) (26) 38 (Figure 5) (26)
39 (Figure 5) (26) 40 (Figure 5) (26)
41 (Figure 5) (26) 42 (Figure 5) (26)
43 (Figure 5) (28,40) 44 [CNB023]
(Figure 5)
(29)
45 (Figure 6) (30) 46 (Figure 6) (30)
47 (Figure 6) (30) 48 (Figure 6) (30)
49 (Figure 7) (33,52) 50 (Figure 7) (33,52)
51 (Figure 7) (33) 52 (Figure 7) (33)
53 (Figure 7) (33) 54 (Figure 7) (33)
55 (Figure 7) (33,52) 56 (Figure 7) (33)
57 (Figure 7) (33) 58 (Figure 7) (33)
59 (Figure 7) (33) 60 (Figure 7) (33)
61 (Figure 7) (33) 62 (Figure 8) (38,61,62)
63 (Figure 8) (38) 64 (Figure 8) (38)
65 (Figure 8) (38) 66 (Figure 8) (38)
67 (Figure 8) (38) 68 (Figure 8) (38)
69 (Figure 8) (38) 70 (Figure 8) (38)
71 (Figure 8) (38) 72 (Figure 8) (38)
73 (Figure 8) (38) 74 (Figure 8) (38)
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Table 2. List of compounds from 1 to 149 with the figures where they are represented.
Compound References Compound References
1 (Figure 1) (6,7,8,9,10,12,15,16,17,
19,20,21,22,23,26,28,35,
36,37,40,43,44,53,54,59, 61,62)
2 (Figure 1) (6)
3 (Figure 1) (6) 4 (Figure 1) (6) 
5 (Figure 1) (6) 6 (Figure 1) (6)
7 (Figure 1) (6) 8 (Figure 1) (6)
9 (Figure 1) (6) 10 (Figure 2) (7,8,9,10,12,23)
11 (Figure 2) (7,8,9,10,12,23,44) 12 (Figure 2) (7,8,11,14,24,31,34,40,
43,51,56,57,58)
13 (Figure 2) (7,8) 14 (Figure 2) (7,8)
15 (Figure 2) (10,19) 16 (Figure 3) (13)
17 (Figure 3) (15,17,22,54) 18 (Figure 3) (15) 
19 [CNB001] 
(Figure 3)
(15,16,17,18,23,25,27,29,32,41,
42,45,46,48,50,53, 54,55,59)
20 (Figure 3) (15,16,53,59)
21 (Figure 3) (16,17,59) 22 (Figure 3) (16,53,59)
23 (Figure 3) (16,53,55,59) 24 (Figure 3) (15,17,53,54,59)
25 (Figure 3) (15,17,54) 26 (Figure 3) (15,17)
27 (Figure 3) (17,20,40) 28 (Figure 3) (17,30,43,59) 
29 (Figure 3) (17) 30 (Figure 4) (19)
31 (Figure 4) (19) 32 (Figure 4) (19,40)
33 (Figure 4) (19,40) 34 (Figure 4) (19,40)
35 (Figure 4) (19) 36 (Figure 4) (19) 
37 (Figure 5) (26) 38 (Figure 5) (26)
39 (Figure 5) (26) 40 (Figure 5) (26)
41 (Figure 5) (26) 42 (Figure 5) (26)
43 (Figure 5) (28,40) 44 [CNB023]
(Figure 5)
(29)
45 (Figure 6) (30) 46 (Figure 6) (30)
47 (Figure 6) (30) 48 (Figure 6) (30)
49 (Figure 7) (33,52) 50 (Figure 7) (33,52)
51 (Figure 7) (33) 52 (Figure 7) (33)
53 (Figure 7) (33) 54 (Figure 7) (33)
55 (Figure 7) (33,52) 56 (Figure 7) (33)
57 (Figure 7) (33) 58 (Figure 7) (33)
59 (Figure 7) (33) 60 (Figure 7) (33)
61 (Figure 7) (33) 62 (Figure 8) (38,61,62)
63 (Figure 8) (38) 64 (Figure 8) (38)
65 (Figure 8) (38) 66 (Figure 8) (38)
67 (Figure 8) (38) 68 (Figure 8) (38)
69 (Figure 8) (38) 70 (Figure 8) (38)
71 (Figure 8) (38) 72 (Figure 8) (38)
73 (Figure 8) (38) 74 (Figure 8) (38)
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75 (Figure 8) (38) 76 (Figure 8) (38)
77 (Figure 8) (38) 78 (Figure 9) (39,52)
79 (Figure 9) (39,52) 80 (Figure 9) (39,52)
81 (Figure 9) (39,52) 82 (Figure 9) (39)
83 (Figure 9) (39) 84 (Figure 9) (39,52)
85 (Figure 9) (39) 86 (Figure 9) (39)
87 (Figure 9) (39,47,52) 88 (Figure 9) (39,52)
89 (Figure 9) (41,54,55) 90 (Figure 9) (41)
91 (Figure 9) (41) 92 (Figure 9) (41)
93 (Figure 10) (44) 94 (Figure 10) (44)
95 (Figure 10) (44) 96 (Figure 10) (44)
97 (Figure 11) (49) 98 (Figure 11) (49)
99 (Figure 11) (49) 100 (Figure 11) (49)
101 (Figure 11) (49) 102 (Figure 11) (49)
103 (Figure 11) (49) 104 (Figure 11) (49)
105 (Figure 11) (49) 106 (Figure 12) (52)
107 (Figure 12) (52) 108 (Figure 12) (52)
109 (Figure 12) (52) 110 (Figure 12) (52)
111 (Figure 12) (52) 112 (Figure 12) (52)
113 (Figure 13) (53,59) 114 (Figure 13) (53,59)
115 (Figure 13) (53,59) 116 (Figure 13) (53,55,59)
117 (Figure 13) (53) 118 (Figure 13) (53)
119 (Figure 13) (53,54,59) 120 (Figure 13) (53)
121 (Figure 13) (53) 122 (Figure 13) (53)
123 (Figure 13) (53) 124 (Figure 13) (53)
125 (Figure 14) (54,59) 126 (Figure 14) (54,60)
127 (Figure 14) (55) 128 (Figure 14) (59)
128 (Figure 14) (59) 130 (Figure 14) (59)
131 (Figure 14) (60) 132 (Figure 14) (60)
133 (Figure 14) (60) 134 (Figure 15) (61,62)
135 (Figure 15) (61,62) 136 (Figure 15) (61,62)
137 (Figure 15) (61,62) 138 (Figure 15) (61)
139 (Figure 16) (63) 140 (Figure 16) (63)
141 (Figure 16) (63) 142 (Figure 16) (63)
143 (Figure 16) (63) 144 (Figure 16) (63)
145 (Figure 17) (64) 146 (Figure 17)  (64)
147 (Figure 17) (64) 148 (Figure 17) (64)
149 (Figure 17) (64)
SYNTHESIS AND REACTIVITY 
Many of these compounds were prepared by the clas-
sical method of reacting hydrazines with b-dicarbonyl 
compounds; since curcumin is “symmetrical” only one 
tautomer (R1 = H) and one isomer (R1 ≠ H) can be ob-
tained. Others were obtained by reaction of pyrazoles 
at position 1, i.e. replacing the N-H proton by another 
group. In this way were obtained N-methyl, N-benzyl, N-
CH2CH2OH, N-acyl, N-COR, etc. but not N-aryl derivati-
ves. Some interesting transformations were reported; an 
example is the reduction of 34 by NaBH4 to afford the 
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allylic alcohol 36 (19) and the synthesis of the elaborated 
compound 48 (30). 
The name “hydrazinocurcumin” has been used for 1 and 
that of hydrazinobenzoylcurcumin for 12 (7), in both ca-
ses incorrectly.
It is suspected that the structure of the products reported 
in reference 26 may be wrong. For instance, the N-hy-
drazinopyrazole 38 was obtained from the N-bromo 37, 
by reacting with hydrazine in ethanol, but this class of 
compounds is unknown. N-nitrosopyrazoles, like 39, N-
CH2OH pyrazoles like 41 and N-formylpyrazoles like 42 
are expected to be rather unstable.
The three most interesting compounds are 1, 12 and 19 
[CNB001] (44 [CNB023] could become important in due 
time). If, from the chemical point of view, 1, 19 and 44 are 
standard pyrazoles, pyrazole 12 has a weird history. 
Compound 12 is 4-(3,5-bis((E)-4-hydroxy-3-
methoxystyryl)-1H-pyrazol-1-yl) benzoic acid (often sold 
as its sodium benzoate). When described for the first 
time (7,8), it was called “Hydrazinobenzoylcurcumin”, 
and other authors named it 4-{3,5-Bis-[2-(4-hydroxy-
3-methoxy-phenyl)-ethyl]-4,5-dihydro-pyrazol-1-yl}-
benzoic acid (HBC). The addition of the 4,5-dihydro term 
made it a 2-pyrazoline, and it was represented as such 
(11,31)! The compound has two code names HBC and 
CTK7A and it is commercially available as its sodium salt; 
again both suppliers (Merck Millipore, US Biological Life 
Sciences) made errors in the structural representation, 
the name and even the molecular formula; actually pa-
tents use the 4,5-dihydropyrazol-1-yl)benzoate wrong 
name (65). We hope that the present review will help to 
put things straight regarding compound 12. 
STRUCTURAL STUDIES 
A large number of compounds are derivatives of curcumin 
itself, so when N-H (1) there are no problems of tautome-
rism and when N-R (12, 17-29, 37-42, 45-61, 78-93, 106-
119, 125-130) there are no issues about isomerism. There 
are other pyrazoles where the substituents at positions 3 
and 5 are identical (2, 11, 14-16, 30-36, 44, 94-96, 97-101, 
102-105, 120-124) and therefore the same conclusions 
apply.
Pyrazoles have been considered as blocked tautomeric 
forms of the keto-enol of curcumin (66), but this idea, rela-
ted to the aromaticity of the chelated enols of b-diketones 
(67,68),  seems to us a little far-fetched. There are several 
cases where both tautomers are different (Figures 8, 15, 
16, 17) but the only studies (NMR, crystallography, DFT 
calculations) on the tautomerism come from our group 
(61,62,63,64). It is possible that the fact that there is no 
clear relationship between tautomerism and biological ac-
tivity explains the lack of studies about the tautomerism of 
pyrazoles related to curcumin in the literature. Since there 
are no examples of isomerism (R1 ≠ H and R3 ≠ R5), no 
spectroscopic studies have been carried out to determine 
the structure of the pyrazoles, i.e. which substituent is at 
position 3 and which at position 5.
BIOLOGICAL PROPERTIES 
We will start discussing the idea, previously mentioned, 
that pyrazoles are isosteres of the enols of b-dicarbonyl 
compounds. The question is: “is this a rationale used for 
the design of curcuminoid pyrazoles?” or “is it an a pos-
teriori rationalization’” when the pyrazoles, and particularly 
1, proved to be superior to curcumin? The first researcher 
that reported pyrazoles did not use this kind of argument in 
1991 (6), and in 2002, the authors commented that “con-
verting the keto-enol moiety to the corresponding pyrazole 
led to increased cytotoxicity against various cell lines”, 
without any hypothesis about isosterism (9). It was not be-
fore 2007 that the argument that pyrazoles are isosteric 
with the enol of curcumin has been used (15,16,17,19,20,
26,28,30,37,38,44,59,69).
Besides this reasoning, others were put forward to justify 
the good results obtained with pyrazoles (much better 
than with isoxazoles): i) the presence of an N–H group is 
necessary for its potency (a fact clearly not general con-
sidering compounds 12, 19 and 44) (16,19); ii) curcumin 
enol form was found to be responsible for its rapid degra-
dation, degradation that can be prevented by transforming 
it into a pyrazole derivative (extremely stable at physiologi-
cal pH) (37); iii) formation of pyrazole derivatives imposes a 
conformational constraint that is beneficial for activity, that 
is seemingly increased by rigidification (38); iv) curcumin-
derived pyrazoles minimize the metal chelation properties 
of curcumin (17,44).
Concerning the relationships between biological proper-
ties and curcumin structure, the most elaborate contribu-
tion is that of Airoldi, La Ferla et al. (30) who carried out 
molecular mechanics (MM) and molecular dynamics (MD) 
to compare curcumin with compound 45 (Figure 6) (see 
Figure 18).
Figure 18. Comparison of the geometries of curcumin 
and that of pyrazole 45, modified from reference 30.
With the exception of one publication that dealt with cur-
cuminoid pyrazoles compounds 97-105 as liquid crystals 
(Figure 11) (49), all the remaining articles report the phar-
macological properties of curcuminoid pyrazoles. We have 
already published two reviews on the medicinal chemistry 
of pyrazoles (70,71), and we will discuss curcuminoid pyr-
azoles by pharmacological fields following the same order 
as in reference 70, omitting those that are empty, such as 
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antidepressants, antipsychotics, anxiolytics, sedatives 
and hypnotics. Being curcumin derivatives, it is normal that 
the most tested activities are related to those of curcumin 
itself: cancer, neurodegenerative diseases (Alzheimer, Par-
kinson), anti-inflammatory and anti-oxidant properties (72).
Anticonvulsants, analgesics, anti-Parkinson and anti-
Alzheimer drugs
- Analgesics (36): Pyrazole 1 has a peripheral antinocicep-
tive activity that is comparable to that of salicylates. This 
activity is related to its ability to inhibit COX and LO en-
zymes (6).
- Anti-Parkinson drugs: Jayaraj et al. reported in three pa-
pers (42,45,46)  the therapeutic potential of 19 [CNB001] 
in the treatment of Parkinson disease. Curcuminoid pyr-
azoles, particularly 1 and 21, inhibit deposition of the neu-
rotoxic a-synuclein aggregates in the brain (59).
- Anti-Alzheimer drugs: Schmidt et al. (15,17) reported that 
curcuminoid pyrazoles inhibit the b-amyloid precursor pro-
tein metabolism, the most active compounds being 17 and 
18. Schubert’s derivatives 19 [CNB001] and 44 [CNB023] 
were useful neurotrophic drugs for cognitive enhancement 
and treatment of Alzheimer’s disease (AD) (29).  Pyrazole 
45 is a ligand of Ab peptides and therefore useful for treat-
ing AD (30). The neuroprotective properties of 19 were re-
ported by Schubert et al. (18). The same compound 19 
[CNB001] restores membrane homeostasis disrupted after 
traumatic brain injury (TBI) (25), and it has been proposed 
to treat ischemic stroke (32,50).
Pharmacodynamic agents
- Antithrombotics. Compounds 1 and 11 show higher 
thrombin inhibition than 91 and 92 (44). 
Agents acting on metabolic diseases and on endocrine 
functions
- Anti-inflammatory drugs and anti-arthritics: The parent 
compound 1 is a powerful 5-lipoxygenase (LO) and cyclo-
oxygenase (COX) inhibitor (6);  SAR studies revealed that 
replacement of the b-diketo fragment of curcumin by a 
pyrazole ring significantly enhances COX2/COX1 selectiv-
ity (compounds 1, 10, 11) (12). Our personal contribution 
was aimed at the treatment of inflammatory bowel disease 
(IBD), Figure 15 (62, 134 -138) (61) and to the design of 
inhibitors of the different isoforms of the nitric oxide syn-
thase (NOS) (1, 62, 134-137, 139-149) (63,64,73).  
 - Hypoglycemic, hypolipidemic and antiobesity agents. 
Treatment of obesity-associated insulin resistance by us-
ing 19 [CNB001] has been described (48). A study report-
ing the hypoglycemic properties of pyrazoles 19 and 116 
has been published (55).
Chemotherapeutic agents
- Anticancer drugs: Kwon et al. published four papers on 
the antiproliferative properties of curcuminoid pyrazoles. 
The most interesting compounds are 1 and 12 (HBC or CT-
K7A). Compound 1 is an inhibitor of endothelial cell prolif-
eration; 1 potently inhibited the proliferation of bovine aor-
tic endothelial cells (BAECs) at nanomolar concentrations 
(IC50 = 520 nM) without cytotoxicity (7,8). Compound 12 in 
flexible docking models demonstrated that it is compatible 
with the binding cavity for a known inhibitor, W7, in the C-
terminal hydrophobic pocket of Ca2+/calmodulin (11). Its 
mechanism consists in inducing sustained phosphoryla-
tion of ERK1/2 and subsequently activating p21WAF1 ex-
pression in HCT15 cells. Moreover, 12 reversibly induced 
the G0/G1 cell cycle arrest in the cells (14). Finally, these 
authors showed that 12 inhibits the androgen receptor 
(AR) activity by targeting the AR amino-terminal domain 
and suggest potential usefulness of 12 for effective treat-
ment of castration-resistant prostate cancer (CRPC) (58).
Lee et al. prepared and evaluated for in vitro cytotoxicity 
against a panel of human tumor cell lines four curcuminoid 
pyrazoles 1, 10, 11 and 15 (9,10). Compound 1 was ac-
tive in all cell lines, whereas, compounds 10 and 11 exhib-
ited selective activity against the 1A9 (breast cancer) cell 
line. However, as potential androgen receptor antagonists 
against two human prostate cancer cell lines, converting 
the b-diketone moiety to the corresponding pyrazole de-
rivative greatly reduced the activity.
A series of pyrazoles, 1, 15, 30-36, were evaluated against 
two breast cancer cell lines, which resulted in the identifi-
cation of several compounds that exhibit anti-proliferative 
activity. These data were compared with their electrophi-
licity (1,4-conjugate addition of benzyl mercaptan, see also 
21). The pyrazoles are more potent than the correspond-
ing isoxazoles but less than curcumin and its derivatives. 
The most potent compound is 1 (MCF-7, IC50 = 4.2 μM) 
(19). Against prostate and breast cancer lines, pyrazole 1 
(IC50 5.4 μM in average) is three times more potent than its 
N-methyl derivative 27 (IC50 16.1 μM in average) (20). The 
anti-tumor properties of 1 have been the subject of many 
studies (for a review, see reference 35): pro-apoptotic ef-
fects on liver cancer (21); cytotoxic effect on Ehrlich asci-
tes cells (EAC) viability (26); free-radical scavenging activ-
ity and inhibition of the proliferation of A549 cells under 
serum-free conditions (37); tubulin-binding properties and 
anti-mitotic agents potentially selective for cancer cells 
(38);  interaction with protein kinase-Cδ (PKC-δ), especially 
with the activator-binding second cysteine-rich C1B sub-
domain; compared with curcumin, pyrazole 1 exhibited 
increased cell growth inhibitory and pro-apoptotic effects 
in liver cancer HA22T/VGH cells as well as in other tumor 
cell types (40). Another much studied compound is 12 
[CTK7A], especially by Zhou et al. (51,56,57) that have re-
ported that it induces autophagy in A549 lung cancer cells 
through activating AMP-activated protein kinase (AMPK) 
signal (57). 12 [CTK7A] is an inhibitor of nitric oxide-medi-
ated histone hyperacetylation in oral cancer (24). 
Ahsan et al. evaluated the in vitro anticancer activity of 
eleven pyrazoles, 78-88, on 60 cell lines (39,40). The most 
active is compound 87, the 1-benzoylpyrazole derived 
from curcumin, which showed GI50 values between 0.008 
and 1.9 μM in a 5-dose assay. 122 [Pculin02H] inhibits 
proliferation and clinical drug resistance of HER2-overex-
pressing cancer cells, being more effective than curcumin 
and other derivatives, even 19 [CNB001] (53). Our studies 
on the effects of curcuminoid pyrazoles 1, 62 and 139-
149 on cancer cells and on the expression of telomerase 
related genes were recently published (74).
Antibacterial and antiprotozoal
- Antibacterial: Pyrazoles 51, 59 and 61 showed remark-
able antibacterial activities (33). Pyrazoles 89-92 inhibit S. 
aureus with MIC between 0.06 and 0.25 mg/mL (41). 
- Antimalarial: Pyrazoles 1, 19-22 were tested as antima-
larial agents: the most potent were 1 and 21 that can be 
considered a novel class of highly selective P. falciparum 
inhibitors (16). Pyrazoles 49, 50, 55, 78-81, 84, 87, 88, 106-
112 were prepared for possible PfRIO-2 kinase inhibitory 
action, an interesting approach to find anti-malarial com-
pounds; the most active pyrazole being the para-fluoro 
derivative 80 (52).
It is clearly apparent that other fields should be explored 
since it is by no means evident that curcuminoid pyrazoles 
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must have the same biological properties as curcumin. 
They are not only “enhanced curcumins” but compounds 
with their own pharmacological profile
CONCLUSION
From our review it can be withdrawn that a large number of 
pyrazoles, isosteres of the curcumin enol form, have been 
synthesized from b-dicarbonyl compounds and hydrazine 
derivatives, proving to have interesting biological proper-
ties to fight cancer, neurodegenerative diseases, or inflam-
mation and oxidation processes. Their activity is related to 
the conformational constraint arising from the heterocyclic 
ring and their potency to the presence of an N–H group. 
Contrary to curcumin, which is rapidly degradated at phy-
siological pH, they are stable and minimize its metal chela-
tion properties. It is expected that new pyrazole structures 
will be addressed in the future in which a fine tuning of 
the substitution pattern in the styryl branch will improve 
the pharmacological activities already found or discover 
new ones.
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